Recent News Releases
For investor-related news, see our ASX releases here.
Nov 3, 2022Cicada Innovations to operate new Melbourne-based biotech incubator to drive translation of world-class medical research
CSL, WEHI, and the University of Melbourne today announced the appointment of an independent operator to oversee and manage the new start-up incubator which will support and grow early-stage Australian biotech companies, providing both lab and office spaces.
Nov 2, 2022Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022
Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL's three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in...
Nov 1, 2022CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus...
Oct 26, 2022
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY), today announced the company has entered into a Strategic Option and License Agreement with Arizona-based Translational Sciences for their enhanced thrombus dissolving drug candidate, TS23.
Oct 20, 2022
Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously (see Vifor Pharma AG's ad hoc announcement of August 2, 2022).